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in Primary Percutaneous Coronary Intervention
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Peter Clemmensen, MD,* Lene Kløvgaard, RN,* Anne Kaltoft, MD,† Thomas Engstrøm, MD,*
Hans E. Bøtker, MD,† Kari Saunamäki, MD,* Lars R. Krusell, MD,† Erik Jørgensen, MD,*
Hans-Henrik T. Hansen, MD,* Evald H. Christiansen, MD,† Jan Ravkilde, MD,† Lars Køber, MD,*
Klaus F. Kofoed, MD,* Leif Thuesen, MD†
Copenhagen and Skejby, Denmark
Objectives The purpose of this study was to evaluate the use of distal protection during percutaneous coronary intervention
(PCI) for ST-segment elevation myocardial infarction (STEMI) in native coronary vessels.
Background Embolization of material from the infarct-related lesion during PCI may result in impaired myocardial perfusion
and worsen the prognosis. Previous attempts to protect the microcirculation during primary PCI have had con-
flicting results.
Methods We randomly assigned 626 patients with STEMI referred within 12 h to have PCI performed with (n  312) or
without (n  314) distal protection. The primary end point was complete (70%) ST-segment resolution de-
tected by continuous ST-segment monitoring. Blood levels of troponin-T and creatine kinase-MB were monitored
before and after the procedure, and echocardiographic determination of the left ventricular wall motion index
(WMI) was performed before discharge.
Results Patients were well matched in terms of demographic and angiographic baseline characteristics. There was no
significant difference in the occurrence of the primary end point (76% vs. 72%, p  0.29), no difference in maxi-
mum troponin-T (4.8 g/l and 5.0 g/l, p  0.87) or maximum creatine kinase-MB (185 g/l and 184 g/l,
p  0.99), and no difference in median WMI (1.70 vs. 1.70, p  0.35). The rate of major adverse cardiac and
cerebral events (MACCE) 1 month after PCI was 5.4% with distal protection and 3.2% with conventional treat-
ment (p  0.17).
Conclusions The routine use of distal protection by a filterwire system during primary PCI does not seem to improve mi-
crovascular perfusion, limit infarct size, or reduce the occurrence of MACCE (Drug Elution and Distal Protec-
tion During Percutaneous Coronary Intervention in ST Elevation Myocardial Infarction; NCT00192868).
(J Am Coll Cardiol 2008;51:899–905) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.10.047p
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sercutaneous coronary intervention (PCI) improves the
utcome compared with fibrinolysis treatment in patients
ith ST-segment elevation myocardial infarction (STEMI)
1–4). However, the prevalence of patients with poor
yocardial perfusion and lack of myocardial salvage after
rom the *Department of Cardiology and Cardiac Catheterization Laboratory,
igshospitalet, University of Copenhagen, Copenhagen, Denmark; and the †Depart-
ent of Cardiology, Aarhus University Hospital, Skejby, Denmark.(
Manuscript received August 16, 2007; revised manuscript received October 10,
007, accepted October 22, 2007.rimary PCI, factors known to be associated with poor
linical outcomes, is considerable, leaving space for im-
rovements in the acute treatment (5–7).
Previous studies have demonstrated that thrombus mate-
ial can be retrieved in a considerable number of cases, some
f them with favorable clinical outcomes (8 –11). However,
andomized studies have not demonstrated any beneficial
ffect using thrombectomy catheters or aspiration of the
tagnant blood column proximal to an occluded balloon
ituated distal to the lesion after stent deployment
12,13). A filterwire system has proven useful to improve
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Distal Protection in AMI March 4, 2008:899–905the clinical outcome in connec-
tion with PCI in saphenous
vein grafts (14). We performed
a trial to evaluate whether the
use of a filterwire system could
limit the damage of embolized
material during PCI in patients
with a large STEMI presenting
within 12 h of symptom onset.
In addition, we examined the
impact of using drug-eluting
versus bare-metal stents in these
patients.
Methods
tudy design and patients. The DEDICATION (Drug
lution and Distal Protection in ST-Elevation Myocardial
nfarction) trial was a randomized study of distal protection
r conventional treatment and implantation of drug-eluting
r bare-metal stents during primary PCI conducted at 2
igh-volume invasive cardiology centers in Denmark.
Patients with chest pain of 30 min duration presenting
ithin 12 h and a total ST-segment elevation of 4 mm in
t least 2 contiguous leads of the electrocardiogram (ECG)
ere eligible for enrollment provided they were 18 years
f age and had a high-grade stenosis or occlusion of a native
oronary artery without excessive tortuosity or calcification
rohibiting advancement of a filterwire to the distal vascular
ed of the vessel. Exclusion criteria were history of a
revious myocardial infarction in the target vessel area,
ulprit lesions in unprotected left main coronary arteries or
aphenous vein grafts, gastrointestinal bleeding within 1
onth, childbearing potential or pregnancy, known renal
ailure, life expectancy 1 year, and linguistic problems.
he study protocol was approved by the local ethics com-
ittees, and all patients gave written informed consent.
andomization and procedures. All patients were pre-
reated with 3- to 500-mg aspirin, 300- to 600-mg clopi-
ogrel, and 10,000-IU unfractionated heparin as soon as
ransportation to the catheterization laboratory was ar-
anged. A beta-blocker was administered at the discretion of
he transportation team according to blood pressure and
eart rate. Provided there was no contraindication, patients
ere treated with a glycoprotein IIb/IIIa receptor blocker at
heir arrival in the catheterization laboratory. Coronary
ngiography was performed and the culprit lesion identified.
guidewire was advanced through the highly stenosed or
ccluded lesion and dilatation with a small balloon, 1.5 or
.0 mm in diameter, performed to allow visualization of the
eripheral vascular bed. If the operator judged that a
lterwire (FilterWire-EZ, Boston Scientific, Santa Clara,
alifornia) or a SpiderX protection device (eV3, Minneap-
lis, Minnesota) could be advanced through the lesion,
entral telephone randomization was performed by comput-
Abbreviations
and Acronyms
ECG  electrocardiogram
MACCE  major adverse
cardiac and cerebral events
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
TLR  target lesion
revascularization
WMI  wall motion indexrized assignment stratified with regard to gender and the eresence of diabetes (15). Randomization to distal protec-
ion or conventional treatment was followed by randomiza-
ion to implantation of a drug-eluting or a bare-metal stent
n the infarct-related lesion. All stents were implanted under
igh pressure (12 atms). Implantation of more than 1
tent of the same type was allowed to cover the entire lesion.
oth operator and patient were aware of the assigned
reatment. Clopidogrel was prescribed for 1 year and aspirin
ndefinitely.
uantitative coronary angiography analysis. Angio-
raphic lesion characteristics were evaluated by independent
ore laboratory technicians unaware of the treatment sequence
sing the MEDIS system (16,17). Angiograms were acquired
n projections with optimal outlining of the lesions with a
inimum of foreshortening and overlap from side branches.
ontinuous ECG ST-segment monitoring. Traditional
2-lead ECGs were acquired in the pre-hospital phase, and
n arrival at the catheterization laboratory patients had
adiolucent carbon fiber electrodes mounted (Ambu Blue
ensor QR electrodes, Ambu A/S, Ballerup, Denmark),
nabling ST-segment monitoring during and after PCI as a
urrogate for improvement in microvascular perfusion (18).
he analog ECG signals were digitized at a sample rate of
00 Hz. The program measures the ST-segment deviation
alfway between the J-point and the start of the T-wave in
ach lead compared with the first acquired 12-lead ECG. A
ew value is appended to the trend line every 30 s, based on
easurements of median beats derived from a newly ac-
uired 10-s epoch of the ECG, and the measured values for
ll 12 leads are stored every 30 s for 90 min after the PCI.
Standard 12-lead ECGs were analyzed manually. Com-
ercial software (CodeStat Suite, Medtronic Emergency
esponse Systems, Redmond, Washington) was used for
he analysis of continuous ST-segment monitoring data.
he maximal cumulated level of ST-segment deviation
efore primary PCI was estimated by summating the
aximal pre-interventional level of ST-segment elevation in
ach anterior lead (0.1 mV ST-segment elevation required
n I, aVL, V4 to V6, and 0.2 mV in V1 to V3) and
onanterior lead (0.1 mV ST-segment elevation required
n II, III, aVF, V5 to V6), respectively. In case of posterior
all involvement, numerical ST-segment deviations 0.1
V in V1 to V4 contributed to the maximal cumulated
T-segment deviation. Post-interventional ST-segment mon-
toring data were evaluated to estimate absolute ST-segment
levation 30, 60, and 90 min after insertion of the guidewire,
chievement of 70% ST-segment resolution, and time to
chievement of 70% and 100% ST-segment resolution.
ardiac markers and echocardiography. Plasma concen-
rations of creatine kinase-MB and troponin-T were mea-
ured before and at least twice with a 6-h interval after the
CI to include the peak level of both biomarkers during
ospitalization. Echocardiography was performed within 2
o 5 days after the PCI procedure and before discharge. Left
entricular systolic function was assessed by 2-dimensional
chocardiography using a wall motion index (WMI) score
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March 4, 2008:899–905 Distal Protection in AMIividing the left ventricle into 16 segments, attributing a
core to each segment, and calculating the average (19). The
core reflects dyskinesia (1), akinesia (0), hypokinesia (1),
nd normokinesia (2). Wall motion index multiplied by 30
ives an estimate of the left ventricular ejection fraction.
all motion indexes were graded by an operator who was
linded to the treatment allocation.
tudy end points. The primary end point of the study was
he rate of patients with 70% ST-segment resolution 90
in after PCI. Secondary end points were time to 70%
T-segment resolution, maximal level of cardiac biomark-
rs, echocardiographic WMI at discharge, and the rate of
ajor adverse cardiac and cerebral events (MACCE) oc-
urring within 30 days after treatment: death, nonfatal
einfarction, disabling stroke, and target lesion revascular-
zation (TLR).
A myocardial infarction was defined as a total creatine
inase elevation 2 times the upper normal limit with a
oncomitant increase in creatine kinase-MB blood concen-
ration in the presence of an acute coronary syndrome.
einfarction was defined as a myocardial infarction in the
arget vessel area. Stroke was defined as development of
isabling neurologic symptoms and objective findings last-
ng 24 h. Target lesion revascularization was defined as
epeat revascularization (percutaneously of the target lesion
r surgical of the vessel containing the target lesion) in the
resence of documented ischemia and a significant stenosis/
cclusion of the infarct-related lesion.
tatistical analysis. The trial involves a factorial design
valuating the effect of treatment with versus without distal
rotection and implantation of drug-eluting versus bare-
etal stents. With a power of 80% and a 2-sided type 1
rror of 5%, we calculated that a total of 450 patients should
e included to detect a 12% increase in the primary end
oint from the anticipated 68% (12) in the conventionally
reated group to 80% in the group treated with distal
rotection. With an expected 25% rate of attrition, 300
atients should be included in each arm evaluating distal
rotection or not.
All analyses were based on intention-to-treat. Differences
n categorical variables including those in subgroups were
nalyzed by the chi-square test or by the Fisher exact test.
ontinuous variables were analyzed using the Mann-
hitney U test for unpaired samples. The Kaplan-Meier
ethod was used to create survival estimates, and the
og-rank test was used to test differences in these estimates.
ests for interaction between the effect of distal protection
nd stent type were performed using analysis of variance,
ogistic regression, and multivariable proportional hazard
odels as appropriate. All p values were 2-sided.
esults
aseline characteristics and procedural results. From
ay 2005 to November 2006, we screened patients referred cor primary PCI with a STEMI at Rigshospitalet and
kejby Sygehus. Of 1,687 patients 1,061 were excluded: in
8 the screening log was not filled in, the condition of 216
atients did not allow inclusion (clinical or psychological
nstability or unconsciousness), in 162 patients the total
T-segment elevation was 4 mm in contiguous leads, 141
articipated in another study, in 140 patients the operator
udged that the distal vessel did not allow advancement of
he filterwire, 78 patients had onset of symptoms 12 h
efore arrival, 72 could not be included due to linguistic
roblems, 58 had a previous infarction, 43 patients had a
evere other cardiac or noncardiac disease, 35 refused to
articipate, 26 had a culprit lesion in the left main stem or
n a saphenous vein graft, 11 patients had an active gastric
lcer or other intestinal bleeding disorder, and 11 patients
ere admitted for a rescue PCI after fibrinolysis. Thus, 626
atients with STEMI were included in the trial (312 to
istal protection and 314 to conventional treatment). Base-
ine clinical characteristics of the patients were well matched
Table 1), 10% of the patients had diabetes mellitus, and
edian symptom duration from onset to randomization was
pproximately 3 h 20 min.
As shown in Table 2, the 2 groups were also well matched
ith regard to angiographic characteristics. More than
ne-third of the patients had multivessel disease, and nearly
ll lesions were highly stenosed or totally occluded.
Of the patients assigned to distal protection, the filterwire
as successfully advanced and unfolded distally to the lesion
efore stent implantation in 254 of 312 patients (81%). The
pider-X system was used in 39 patients. In 58 patients
aseline Clinical Characteristics of the Patients
Table 1 Baseline Clinical Characteristics of the Patients
Distal
Protection
(n  312)
Conventional
Treatment
(n  314) p Value
Age, yrs* (SD) 62 (12.3) 63 (12.1) 0.27
Male gender (%) 232 (74.4) 226 (72.0) 0.53
Diabetes mellitus (%) 28 (9.0) 37 (11.8) 0.30
Hypertension (%) 100 (32.1) 107 (34.1) 0.61
Treatment for
hyperlipidemia (%)
58 (18.6) 64 (20.4) 0.35
Current smoker (%) 177 (56.7) 158 (50.3) 0.24
Family history of
CAD (%)
114 (36.5) 118 (37.6) 0.80
Previous myocardial
infarction (%)
20 (6.4) 20 (6.4) 1.0
Previous PCI/CABG (%) 16 (5.1) 15 (4.8) 0.62
Symptom onset to arrival,
min* (range)
200 (26–1,350) 199 (40–996) 0.98
Door to balloon,
min* (range)
27 (3–104) 24 (3–92) 0.01
Symptom onset to balloon,
min* (range)
233 (59–1,370) 222 (60–1,027) 0.55
Baseline cumulated ST-
segment deviation,
mV* (range)
1.1 (0.7–2.2) 1.3 (0.8–2.1) 0.13
Values are medians.
CABG  coronary artery bypass grafting; CAD  coronary artery disease; PCI  percutaneous
oronary intervention.
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Distal Protection in AMI March 4, 2008:899–90519%), none of the distal protection systems could be
dvanced to a sufficient landing zone. Stent lengths and
iameters were similar in the 2 groups, and the rate of
rocedural success was high in both groups (Table 3).
hrombolysis In Myocardial Infarction (TIMI) flow grade
was obtained in 95% of patients treated with distal
aseline Angiographicharacteristics of t e Patients
Table 2 Baseline AngiographicCharacteristics of the Patients
Distal
Protection
(n  312)
Conventional
Treatment
(n  314) p Value
Number of diseased
vessels (%)
1-vessel disease 198 (63) 194 (62)
2-vessel disease 83 (27) 85 (27) 0.86
3-vessel disease 30 (10) 34 (11)
Infarct-related artery (%)
RCA 139 (45) 152 (48)
LAD 138 (44) 119 (38) 0.25
LCX 35 (11) 43 (14)
Baseline TIMI flow
grade (%)
0 to 1 209 (67) 213 (68) 0.87
2 to 3 103 (33) 101 (32)
Angiographic lesion
characteristics
Reference vessel
diameter, mm*
(range)
3.50 (2.20–5.00) 3.50 (2.30–5.00) 0.25
Diameter stenosis,
%* (range)
100 (30–100) 100 (50–100) 0.17
Minimal lumen
diameter, mm*
(range)
0.00 (0.00–3.15) 0.00 (0.00–2.00) 0.20
Visible thrombus (%) 213 (68) 236 (75) 0.14
Values are medians.
LAD  left anterior descending coronary artery; LCX  left circumflex artery; RCA  right
oronary artery; TIMI  Thrombolysis In Myocardial Infarction.
rocedural Results
Table 3 Procedural Results
Distal
Protection
(n  312)
Conventional
Treatment
(n  314) p Value
Use of GP IIb/IIIa
inhibitor (%)
301 (97) 302 (96) 0.36
Filterwire attempted (%) 304 (97) 0 —
Filterwire success (%) 254 (81) 0 —
Stent implanted (%) 307 (98) 312 (99) 0.29
Drug-eluting stent (%) 158 (51) 155 (49) 0.81
Stented length,
mm* (range)
18 (6–60) 20 (8–107) 0.83
Stent diameter,
mm* (range)
3.5 (2.0–5.0) 3.5 (2.0–5.0) 0.20
TIMI flow grade 3 post-
procedure (%)
295 (95) 268 (85) 0.01
IABP (%) 4 (1) 6 (2) 0.75
Procedural success (%) 309 (99) 310 (99) 0.69
Values are medians.
GP  glycoprotein; IABP  intra-aortic balloon pump; TIMI  Thrombolysis In Myocardial
nfarction.rotection compared with 85% who received conventional
reatment (p  0.01).
T-segment resolution and myocardial infarct size.
echnical difficulties prohibited recording of the ST-
egments in 23 patients. As delineated in Figure 1 and
able 4, the primary end point of 70% ST-segment
esolution 90 min after PCI occurred in 230 of 302 patients
76%) allocated to distal protection and in 218 of 301
atients (72%) receiving conventional treatment (p  0.29).
Creatine kinase-MB mass and troponin-T concentra-
ions were measured in all but 7 patients, and echocardio-
rams allowed determination of the WMI in 477 (76%)
atients. There was no difference in the rise in cardiac
iomarkers 6 to 18 h after PCI, and echocardiography
erformed before discharge did not show any difference in
MI (Fig. 2).
There were no significant interactions between distal
rotection and stent type and the primary, secondary, or
xplanatory variables, respectively. All p values for interac-
ion were 0.10.
ACCE. Death and stroke occurred with similar fre-
uency 30 days after primary PCI in the groups treated
ith or without distal protection as seen in Figure 3. A
endency toward a higher rate of reinfarction and TLR
as observed in the group treated with distal protection.
o significant difference was observed in MACCE be-
ween the 2 groups.
ubgroup analysis. Figure 4 shows that no differences
ould be detected in any subgroup with regard to the
rimary end point. All p values for interaction were
Figure 1 Complete ST-Segment Resolution
Cumulative frequency curves of patients achieving 70% resolution of the ST-
segment 90 min after primary percutaneous coronary intervention show a
small, insignificant difference in the 2 groups receiving distal protection and
conventional treatment.0.10.
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March 4, 2008:899–905 Distal Protection in AMIiscussion
he present study evaluated the ECG, cardiac biomarker,
chocardiographic, and clinical outcomes of routine use of a
istal filterwire protection device in patients with a large
TEMI. Distal protection was successfully performed in
ore than 80% of the patients assigned to this treatment.
owever, there appeared to be no significant differences in
ny of these parameters between the 2 groups, indicating
hat distal protection has no short-term benefit on myocar-
ial function. In the PROMISE (Protection Devices in PCI
reatment of Myocardial Infarction for Salvage of Endan-
ered Myocardium) study, the filterwire was also used to
rotect the distal coronary vasculatory bed in patients with
yocardial infarction referred within 48 h of symptom
nset (20). In that study, approximately two-thirds of the
atients had STEMI, but coronary perfusion measured by a
oppler flow wire did not show any difference whether
CI was performed under distal protection or not. Infarct
ize determined by magnetic resonance as the volume of
he left ventricle with delayed enhancement was similar
n the 2 groups.
The prognostic utility of ECG ST-segment resolution
fter primary PCI has been described previously (21,22),
nd the value of continuous ST-segment monitoring after
he procedure was stressed in a recent study, which also
emonstrated the heterogeneous ST-segment changes in
atients with STEMI (18). None of these sensitive prog-
ostic markers was affected by the use of a filterwire during
rimary PCI in the present study.
Distal protection by inflation of a balloon and concomi-
ant aspiration of blood and debris released from the stented
esion was performed in the EMERALD (Enhanced Myo-
ardial Efficacy and Removal by Aspiration of Liberated
ebris) randomized trial, including both patients with
TEMI and patients referred for rescue angioplasty (12).
espite a relatively high success rate with regard to protec-
ion during stent deployment and extraction of visible debris
n more than 70% of the cases, no improvement could be
etected in the primary end point, complete ST-segment
esolution during ECG monitoring after PCI. In addition,
nfarct size determined by 99mTc-sestamibi single-photon
T-Segment Monitoring Data
Table 4 ST-Segment Monitoring Data
70% ST-segment resolution within 90 min of first wire
Time from first wire to 70% ST-segment resolution (min)
100% ST-segment resolution within 90 min of first wire
Time from first wire to 100% ST-segment resolution (min)
Single-lead ST-segment elevation 30 min after first wire (mV)
Single-lead ST-segment elevation 60 min after first wire (mV)
Single-lead ST-segment elevation 90 min after first wire (mV)
ontinuous variables are presented by their medians (interquartile range).mission computerized tomography, the coprimary end ooint of the study, tended to be larger in the patient group
ssigned to distal protection. Embolization of thrombus
aterial during manipulation of the device in the infarct-
elated area is an inherent risk of the mechanical interven-
ions that has to be taken into account when the lack of
fficacy of both the EMERALD and the present studies are
nterpreted (23). In addition, the Boston Scientific filterwire
equires a landing zone of the device at least 30 mm distal
o the segment that is going to be stented.
Thrombectomy performed with an aspiration catheter in
atients with STEMI did not have any beneficial impact on
yocardial salvage determined by 99mTc-sestamibi single-
hoton emission computerized tomography in the RESCUE
Routine Thrombectomy in Percutaneous Coronary Interven-
ion for Acute ST-Segment Elevation Myocardial Infarction)
tudy (13). There was no difference between ST-segment
esolution in the 2 groups in that study, whereas the release of
ardiac biomarkers was higher in the thrombectomy group. In
ddition, scintigraphic evaluation showed a significantly
maller final infarct size in the control group. The bulky profile
f the Rescue catheter (Boston Scientific/Scimed, Inc., Maple
rove, Minnesota) may at least theoretically be detrimental to
he vessel wall during aspiration, especially in angulated areas
f the infarct-related artery, besides the potential risk to
mbolize thrombus material with this device as well.
Previous studies reported improvement in coronary blood
ow and ST-segment resolution and a reduction in devel-
pment of large myocardial infarctions by aid of thrombec-
omy using a combined helical cutter and vacuum extraction
ystem or manual thrombus aspiration in patients with acute
yocardial infarction (24–26). In addition, distal emboli-
ation was observed more frequently in the control patients,
finding that was confirmed by a meta-analysis of the use of
hrombectomy devices in patients with acute myocardial
nfarctions (7). However, no beneficial effect was observed
n 30-day mortality in any of these studies, and in a recent
arge randomized study rheolytic thrombectomy resulted in
significant increase in the scintigraphic infarct size com-
ared with the control treatment (27).
As opposed to the results of the PROMISE and
MERALD trials, we found a 10% increase in the fraction
l Protection
 302)
Conventional
Treatment
(n  301) p Value
(76%) 218 (72%) 0.29
(0–80) 26 (4–90) 0.28
(70%) 198 (66%) 0.23
(0–90) 30 (4–90) 0.21
(0.04–0.26) 0.13 (0.05–0.26) 0.44
(0.04–0.20) 0.11 (0.04–0.21) 0.24
(0.03–0.17) 0.09 (0.03–0.19) 0.43Dista
(n
230
26
211
26
0.12
0.09
0.08f patients who obtained TIMI flow grade 3 after PCI
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Distal Protection in AMI March 4, 2008:899–905erformed with distal protection. It is possible that distur-
ances in the blood flow pattern may not only be caused by
mbolization of thrombotic plaque material per se, but may
lso be a sign of reperfusion damage or indicate a condition
f irreversibly impaired microvascular circulation. Blush
rade was not determined, and it is possible that ST-
egment resolution and circulating biomarkers are not
dequately sensitive to detect small improvements in the
icrocirculation. In addition, it cannot be excluded that the
Figure 2 Cardiac Biomarkers and WMI
Maximal levels of cardiac biomarkers and echocardiographic determination of
left ventricular wall motion index (WMI) after primary percutaneous coronary
intervention in the 2 groups receiving distal protection and conventional treat-
ment. CK-MB  creatine kinase-MB.evices used in this or other trials were inadequate torevent distal embolization, and that distal protection is
ndicated in the proportion of STEMI patients in whom a
rotection device can be successfully advanced and unfolded
istally to a well-defined thrombus without embolization of
hrombus material by the device itself, with subsequent
alloon dilatation and deployment of stents.
Recent research did not indicate any safety problems
sing drug-eluting stents during primary PCI (28,29).
Figure 3 MACCE After 30 Days
Major adverse cardiac and cerebral events (MACCE) 30 days after primary
percutaneous coronary intervention. TLR  target lesion revascularization.
Figure 4 Subgroup Analyses for the Primary End Point
Subgroup analyses with regard to complete ST-segment resolution. BMS 
bare-metal stent; CX  circumflex coronary artery; DES  drug-eluting stent;
DM  diabetes mellitus; LAD  left anterior descending coronary artery; RCA
 right coronary artery; TIMI  Thrombolysis In Myocardial Infarction.
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March 4, 2008:899–905 Distal Protection in AMIowever, in light of the slightly increased risk of late stent
hrombosis occurring after implantation of drug-eluting
tents (30–32), a risk that may potentially be considerably
levated in patients with a current burden of thrombus in
he lesion to be stented, long-term observation of these
tudies is needed to make firm statements of stent choice in
atients with STEMI.
Together with the results of other trials evaluating the
ffect of distal protection and thrombectomy, the results of
he present study demonstrate that routine use of adjunctive
echanical devices cannot be advocated during PCI treat-
ent of patients with STEMI.
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